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and Cooper, 2005; Abler et al., 2006, 2007; Yacubian et al., 2006; 
Jensen et al., 2007). Therefore, such paradigms are well suited to test 
the dopamine hypothesis of schizophrenia indirectly by investigat-
ing mesolimbic–mesocortical activation during reward process-
ing. Aberrant activation in the ventral striatum of patients with 
schizophrenia has been demonstrated for prediction of ﬁ  nancial 
reward (Juckel et al., 2006b; Jensen et al., 2008) and aversive cues 
(Jensen et al., 2008) as well as for reward prediction error (Murray 
et al., 2008). Aberrant activation of prefrontal regions during the 
outcome period of reward paradigms in schizophrenia has been 
described for the medial prefrontal cortex (MPFC) (Schlagenhauf 
et al., 2009) as well as for the right dorsolateral prefrontal cortex 
(DLPFC) (Corlett et al., 2007).
A recent investigation of our group provided support for the 
revised version of the dopamine hypothesis in partially remitted 
patients diagnosed with schizophrenia treated with the atypical 
neuroleptic olanzapine (Walter et al., 2009). Using a monetary 
incentive delay task in fMRI, we found evidence for normal to 
elevated activation in the ventral striatum for the prediction error 
during outcomes of reward. Moreover, cortical regions, namely the 
anterior cingulate gyrus and the right ventrolateral prefrontal cor-
tex (VLPFC) mediating attentional processes and action selection 
were found to be hypoactive during reward processing. Importantly, 
while the above cited studies on schizophrenia directed their focus 
on either reward expectation or outcome signals related to predic-
tion error theory, the ﬁ  nding of dysfunctional activation of the right 
INTRODUCTION
The dopamine hypothesis of schizophrenia (Carlsson and Lindqvist, 
1963; Carlsson et al., 2000) assumes a central role for dopamine in 
the development of psychotic symptoms based on the mechanisms 
of antipsychotic drug action and PET studies on dopamine release 
in patients with schizophrenia following amphetamine intake. 
Although other neurotransmitters play an important role in the 
course of the illness, dopamine is still one of the most important 
scopes of current research on the neurobiology of schizophrenia. 
In its revised form hyperactivation of the mesolimbic dopamine 
system via D2-receptors is suggested to explain positive symptoms 
like delusions or hallucinations, while hypoactivation of the meso-
cortical system via D1-receptors is suggested to explain negative 
symptoms including anhedonia and cognitive impairment (Guillin 
et al., 2007). This view has recently been reframed as the aberrant 
salience hypothesis (Kapur, 2003; Kapur et al., 2006), for similar 
approaches compare (Spitzer, 1997; Heinz, 2002). This hypothesis 
is based on the idea that the mediation of incentive salience is the 
central function of mesolimbic dopamine (Berridge and Robinson, 
2003). The anhedonia hypothesis of dopamine function (Wise 
et al.,  1978) suggests a link between mesolimbic–mesocortical 
hypoactivation and negative symptoms.
Investigating the reward system with functional magnetic reso-
nance imaging (fMRI) has been demonstrated as a reliable way to 
study the physiological function of the mesolimbic–mesocortical 
dopamine system in healthy subjects (Knutson et al., 2001; Knutson 
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representation. Our main result was that we could replicate the ﬁ  nding of aberrant salience 
coding in the right VLPFC in patients with schizophrenia. Furthermore, we found evidence that 
the degree of salience coding in this region was correlated inversely with negative symptoms 
(anhedonia). Results of dopaminergic modulation showed tentative evidence for an inﬂ  uence 
of dopaminergic stimulation, but were not conclusive. In summary, we conclude that the right 
VLPFC might play a crucial role in salience coding and is impaired in schizophrenia.
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VLPFC was revealed by modelling reward salience (Walter et al., 
2009), that is, by comparing the most positive and most negative 
outcomes vs. the most neutral events (compare Section “Methods” 
and Figure 1). In line with the aberrant salience hypothesis of 
schizophrenia salience was thus related to its relevance to future 
behaviour (Cooper and Knutson, 2008): the more salient a cue, the 
greater the chance a subject will need to adapt a future behavioural 
response. Crucially, this response might involve either approach 
or withdrawal; cues related to negative outcomes like danger, loss 
or a need for escape will hold as much salience as cues related to 
positive or rewarding outcomes.
As the ﬁ  nding of schizophrenia associated aberrant salience cod-
ing in the right VLPFC is new, we were interested in replication of 
our index study (study 1) (Walter et al., 2009). For this purpose 
we reanalyzed recently published data of an independent sample 
of patients with schizophrenia and healthy control subjects (study 
2: replication study) (Abler et al., 2008). The ﬁ  rst and primary aim 
was to ﬁ  nd out if we could replicate the ﬁ  nding of aberrant salience 
coding in the right VLPFC in an independent cohort of patients 
with schizophrenia. Secondly, we investigated in both, the index 
and the replication study, if aberrant salience coding was related 
to psychopathological symptoms. We expected to ﬁ  nd a putative 
hyperactivation of the ventral striatum to be related to positive 
symptoms and a putative hypoactivation of the prefrontal cortex 
to be related to negative symptoms. In order to investigate addi-
tional aspects of salience coding, we included a reanalysis of three 
further published reward studies of our group: a healthy control 
sample manipulating reward probability (study 3) (Abler et al., 
2006), a study of restless legs syndrome (RLS)-patients on and off 
their dopaminergic medication (study 4, RLS-Study) (Abler et al., 
FIGURE 1 | SALIENCE in outcome (reward magnitude). Brain activation and 
beta weights in the right VLPFC/anterior insula as found for the interaction of 
contrasts modelling salience in patients suffering from schizophrenia and 
controls scanned with the magnitude paradigm. The beta values were 
extracted from the maximum voxel of the demonstrated activation. The map 
was thresholded at p < 0.005 at the voxel-level and at an extent threshold of 
p < 0.05 at the cluster-level. The interaction contrast is masked by the contrast 
in the controls’ group alone thresholded at p < 0.005 at the voxel-level. The 
coefﬁ  cient “a” taken as a measure of the shape of a U-shaped regression 
curve indicates a more shallow curve the lower the levels and an inverse 
U-shape with negative values. The values in control subjects were signiﬁ  cantly 
higher than in the patients. r/high, r/low, no, o/low, o/high: receipt of high 
reward, receipt of low reward, receipt of no reward, omission of low reward, 
omission of high reward.Frontiers in Behavioral Neuroscience  www.frontiersin.org  February 2010  | Volume 3  |  Article 62  |  3
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2009) and a study with healthy subjects receiving either placebo 
or a single dose of 5 mg of olanzapine (study 5, olanzapine study) 
(Abler et al., 2007). We expected salience coding to be abolished 
by olanzapine in healthy controls and alteration of salience coding 
in RLS patients on their dopaminergic medication.
MATERIALS AND METHODS
Data from ﬁ  ve studies published on monetary reward processing by 
our group (see Table 1) were reanalysed for salience coding during 
outcome. Studies 1 and 2 investigated partially remitted patients 
with schizophrenia medicated with atypical neuroleptics, study 3 
healthy controls, study 4 patients with RLS on and 2–5 days (ﬁ  ve 
half-lives of the respective drug) off their regular dopaminergic medi-
cation (pramiprexole, cabergoline, or ropinirole) and study 5 healthy 
controls receiving a single dose of either placebo or 5 mg olanza-
pine. Groups are characterised in detail in Table 1, more detailed 
 information can be found in the respective publications. Within the 
respective studies, data were analysed during anticipation of reward 
as well as during outcome of reward including prediction error. The 
contrast modelling salience (compare Figures 1 and 2) had only been 
used in study 1 (“index study”) but not in the other published stud-
ies and is reported here for the ﬁ  rst time. Also the correlations with 
psychopathology are reported here for the ﬁ  rst time.
SUBJECTS
Number, gender and age of the subjects investigated can be found 
in Table 1. None of the subjects had a history of major medical or 
neurological illness, besides RLS according to standardized diagnostic 
criteria in study 4. None of the included healthy subjects or RLS 
patients was identiﬁ  ed to have a history of psychiatric illness. Detailed 
FIGURE 2 | SALIENCE and psychopathology (reward magnitude). In 
study 1 (index study) and study 2 (replication study) we found signiﬁ  cant 
negative correlations with anhedonia scores (social anhedonia and physical 
anhedonia, respectively) and the coefﬁ  cient “a” extracted from the VLPFC 
where group differences (controls > patients with schizophrenia) were found, 
that is, lower anhedonia scores predicted a pattern with steeper U-shaped 
curves as found in the controls. Correlations were signiﬁ  cant for the social 
anhedonia scores (p = 0.04) in all subjects, patients and controls in the index 
study 1 and for the physical anhedonia scores in study 2 in all subjects 
(p = 0.03) driven by a signiﬁ  cant effect in the patients (p = 0.02). Anhedonia 
scores were not obtained in three of 16 patients in study 1 and 4 of 12 
patients in study 2.
Table 1 | Studies (re)analyzed in this paper for the salience contrast.
  Subjects   Age   Medication  Reward   Reference
 (Male/female)  (Mean  ± SD)    paradigm
Study 1   7/9 HC  38.0 ± 9.0  Patients all medicated   Magnitude  Walter et al. (2009)
(index study)  8/8 Sx  33.0 ± 10.2  with olanzapine   
Study 2  7/5  HC 36.2  ± 11.2  Patients all medicated with   Magnitude  Abler et al. (2008)
(replication study)  5/7 Sx  36.7 ± 7 .8  various atypical neuroleptics   
Study 3  11/0  HC  24.2  ± 1.3  No medication  Probability  Abler et al. (2006)
(pilot for Study 4)
Study 4   0/12 RLS  55.8 ± 8.8  Patients scanned twice:    Probability  Abler et al. (2009)
(dopaminergic     off-and-on their regular
manipulation)     dopaminergic  medication
Study 5  4/4  HC 55.8  ± 8.8  Healthy controls scanned twice   Magnitude  Abler et al. (2008)
(antidopaminergic     under placebo and 
manipulation)      after 5 mg olanzapine
HC, Healthy controls; Sx, Patients with schizophrenia; RLS, Restless Legs Syndrome; SD, standard deviation.Frontiers in Behavioral Neuroscience  www.frontiersin.org  February 2010  | Volume 3  |  Article 62  |  4
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descriptions of the respective sample characteristics are given in the 
papers referenced. All participants, patients and controls, gave writ-
ten informed consent after complete description of the study. All 
studies were carried out in accordance with the latest version of the 
Declaration of Helsinki and approved by the ethics committee of the 
University of Ulm, Germany or, in case of the replication study by 
the ethics committee of McLean Hospital, Belmont, MA.
RATINGS AND PSYCHOLOGICAL TESTING
Psychopathological ratings refer to the German or English ver-
sion of the Positive and Negative Syndrome Scale (PANSS, Kay 
et al., 1987; Müller, 2002) and the Physical and Social Anhedonia 
Scale (Chapman et  al., 1976; Scherbarth-Roschmann and 
Hautzinger, 1991).
REWARD TASKS
Subjects in all studies were presented with one of two versions of 
a validated paradigm (Abler et al., 2005, 2006), that is, a monetary 
incentive task with a parametric variation of possible wins either 
regarding reward magnitude (Magnitude Paradigm: 1€, 20¢, No 
win; probability of rewards ﬁ  xed at 60%) or reward probability 
(Probability Paradigm: 0%, 25%, 50%, 75%, 100%, magnitude 
of rewards ﬁ  xed at 1€). Studies 1, 2 and 5 were conducted with 
the Probability Paradigm, studies 3 and 4 with the Magnitude 
Paradigm. In short, each of the 60 trials per session started with 
a symbol indicating one of three possible amounts of money 
to win or one of ﬁ  ve probabilities. After an expectation period, 
subjects had to correctly react with a left or right button press to 
one of two symbols (a square or a triangle) within a ﬁ  xed interval. 
Subjects were informed that they did not need to react faster and 
that their chances to win were independent of their reaction times. 
In reacting correctly in the Magnitude Paradigm, they preserved 
themselves a 60% chance to win the announced amount of money 
(1€ or 20¢: win trial). In the Probability Paradigm, the announced 
chance to win 1€ was preserved. In the rest of the trials, subjects 
were not rewarded despite pressing the correct button (omis-
sion trials). Incorrect button presses resulted in a feedback of 
zero Euro at any rate. Win and omission trials as well as the trial 
types (1€, 20¢, no win/0%, 25%, 50%, 75%, 100%) appeared in 
random order. In the control trials (no win/0%) no money was 
announced, subjects only had to press an arbitrary button and 
could not win any money. To make sure that all trials included a 
button press of any kind, subjects were informed that they would 
lose 1€ if no button press occurred. Feedback (outcome) followed 
the targets disappearance and notiﬁ  ed subjects with the amount 
of money they won in the trial.
fMRI ACQUISITION
Data for all studies were acquired on Siemens Scanners (Siemens 
AG, Germany): study 1, 3, 4 and 5 on a 3 Tesla ALLEGRA Scanner, 
study 2 on a 3 Tesla TRIO Scanner. Both scanners were equipped 
with a head coil and used to acquire T1 anatomical volume images 
(1 × 1 × 1 mm voxels) and functional MR images. Twenty-three 
axial slices (study 2: 21) were acquired with an image size of 
64 × 64 pixels and a FoV of 192 mm. Slice thickness was 3 mm with 
0.75-mm gap resulting in a voxel size of 3 × 3 × 3.75 mm. Images 
were angled along a line connecting basal forebrain and basal 
cerebellum. Images were centred on basal structures of the 
brain   including subcortical regions of interest (basal ganglia, 
  orbitofrontal and ventral frontal regions). Functional images 
were recorded using a T2*-sensitive gradient echo sequence 
measuring changes in BOLD-contrast. Four hundred and one 
volumes were obtained during each of the two reward sessions 
at a TR of 1500 ms.
fMRI ANALYSIS
Image processing and statistical analysis were carried out using 
Statistical Parametric Mapping (SPM2, Wellcome Department, 
London, UK). To test for effects of reward salience, the respec-
tive contrast was calculated for each of the studies as depicted 
in  Figures 1 and 2 and explained below in Section “Second 
level analyses”.
Preprocessing
Images of all studies were pre-processed including slice timing, 
realignment to correct for motion artefacts and spatial normali-
zation to standard space. Smoothing was applied with an 8-mm 
Gaussian kernel. Intrinsic autocorrelations were accounted for by 
an autoregressive model of ﬁ  rst order (AR(1)) and low frequency 
drifts were removed via high pass ﬁ  lter.
First level analysis
After preprocessing, ﬁ  rst level analysis was performed on each 
subject estimating the variance of voxels according to a general 
linear model for the Magnitude or Probability Paradigm: the 
three/ﬁ  ve expectation periods, the button press and the ﬁ  ve/eight 
different outcome events were modelled as boxcar functions and 
convolved with the hemodynamic response function. Depending 
on the preceding reward expectation (high/low/no or 0–100%) 
and actual outcome (receipt of reward: r, omission of reward: o), 
the ﬁ  ve/eight outcome events were: Magnitude Paradigm: R/high, 
R/low, no, O/low, O/high reward; Probability Paradigm: (i) 0%; (ii) 
r/25%; (iii) o/25%; (iv) r/50%; (v) o/50%; (vi) r/75%; (vii) o/75%; 
and (viii) 100%. The six realignment parameters were included in 
the models. Contrast images of contrasts between regressors of 
interest were calculated on the single subject level. This approach 
meant that new ﬁ  rst level analyses with ﬁ  ve instead of only three 
(receipt/omission/no reward) outcome regressors were calculated 
for studies 2 and 5, while the ﬁ  rst level analyses of studies 1, 3 and 
4 remained as published.
Second level analyses
Separately for each study, the contrast images of parameter esti-
mates from the ﬁ  rst level analysis were then included in a second 
level group analysis (random-effects model), treating inter- subject 
variability as a random effect to account for interindividual vari-
ance. We computed analyses on the ﬁ  ve/eight outcome events 
(receipt/omission of reward). Effects were tested separately for 
each group (patients/control subjects/on and off medication) and 
by interaction analyses of the groups.
To model the salience of outcome events, we built a regular 
U-shaped contrast as described in the index study: receipt and 
omission of high rewards were weighted with the highest con-
trast values; receipt and omission of low rewards were weighted 
with medium values, and the no reward events with the lowest 
contrast values.Frontiers in Behavioral Neuroscience  www.frontiersin.org  February 2010  | Volume 3  |  Article 62  |  5
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For the new analyses of the studies in this paper, thresholding was 
kept comparable to the respective original investigations. In the index 
study (study 1), whole brain random-effects statistical maps were 
thresholded at p < 0.001 uncorrected for multiple comparisons at a 
cluster size threshold of 15 voxels. In studies 2, 4 and 5 a threshold 
of p < 0.001 uncorrected at the voxel-level for simple contrasts and 
p < 0.005 uncorrected for interaction contrasts at an extent threshold 
of p < 0.05 at the cluster-level was used. If activations remained signiﬁ  -
cant after FDR (false discovery rate) correction for multiple testing at 
p < 0.05, they are indicated in Table 2. In study 3 results are reported at 
a threshold of 0.005 family wise error (FWE) corrected. To ensure that 
the results of the interaction contrasts were clearly driven by actually 
elevated fMRI signal in one group, we computed the respective con-
trasts in the respective group only and used them as inclusive masks. 
Masks were thresholded at p < 0.005 at the voxel-level.
Additional statistics on second level results. Regression analyses on 
the beta values of the peak voxels of activations found were calculated 
externally using the software packages Microsoft Excel and Statistica 
6.0. The regression curve for a U-shaped contrast like our salience con-
trast is best described with a parabolic line that can be characterized by 
a second order equation (ax² + bx + c = y). The coefﬁ  cient “a” can be 
taken as a measure of the shape of the U with lower values indicating 
a more shallow curve and negative values an inverse U-shape.
Correlational analyses
To assess relations between psychopathology and brain activation, we 
calculated planned correlations parallel to those in the index study 
between our main results concerning brain activation, that is, the 
brain regions where group differences were found and the main 
psychopathology scores, PANSS positive, negative, and anhedonia.
Table 2 | fMRI activations as found for the contrast modelling reward salience.
  L/R/M  Z  NV  Max.   Z  NV  Max.   Z   NV  Max. 
       x /y/z     x/y/z       x/y/z
STUDY 1 (INDEX STUDY)  HC (n = 16)  SX (n = 16)  HC > SX
VLPFC/Ant. Ins., BA 47  R  5.19*   119  42/24/−15        3.67   15  39/21/−15
Ant. Cingulate, BA 9/32    4.43   107  9/39/21           
DLPFC, BA 9/46   R  4.26  24  42/36/21           
STUDY 2 (REPLICATION STUDY)  HC (n = 12) SX  (n = 12)  HC > SX
VLPFC/Ant. Ins., BA 47   R  4.68*  86  36/33/−15       3.26*  57  33/30/−9
   4.19*  48  45/18/−18            
 L  3.45*  35  −48/21/−6          
Ant. Cingulate, BA 24/32  M  3.78*  263  −3/36/15       3.70*  137  0/27/27
Med. frontal gyrus, BA 8/9  L            3.91*  112  −15/42/30
Ventral Striatum  R  4.19*  77  9/15/0   3.23  17  12/12/−6    
 L  3.74*  20  −9/9/−3         
Med. Frontal gyrus, BA 10  R        4.10  34  30/51/6     
Post. Cingulate, BA 23/31    3.97*  52  0/−9/27 3.80  51  −3/−21/30    
Thalamus   3.49*  25  −3/−9/9         
Hippocampal area  L  3.45*  29  −21/−33/−6          
 R  3.35*  22  18/−36/−6          
Occipital cortex BA18  L  3.97*  108  −18/102/−3 4.01 22  −18/−99/−6    
 R  4.27*  70  21/−99/0 3.61  41  12/−93−/−3    
Cerebellum R  3.51*  25  27/−54/−27          
STUDY 3 (CONTROLS FOR STUDY 4)    HC (n = 11)           
VLPFC/Ant. Ins., BA 47  R  5.97~  13  30/21/−9         
STUDY 4 (RLS-STUDY)  RLS OFF MEDS (n = 12)   RLS ON MEDS (n = 12)  OFF > ON MEDS
VLPFC/Ant. Insula, BA 47  R  3.65  31  38/28/−18          
  L       3.57  31  −36/20/−14    
DLPFC, BA 9/46  R  4.18  47  52/26/34           
DLPFC, BA 9/44     3.39  22  50/18/24           
Precentral gyrus, BA 6  L  4.15  74  −42/4/28      4.56*  49  −44/4/24
Precentral gyrus, BA 4  R  4.03  20  44/−2/36         
Inf. temporal gyrus, BA 37  R  3.88  35  64/−46/−8          
STUDY 5 (OLANZAPINE STUDY)  HC PLACEBO (n = 8)  HC OLANZAPIN (n = 8)  PLACEBO > OLANZAPINE
No signiﬁ  cant activation    
Brain activation related to the salience of outcome events (receipt of high > receipt of low > receipt of no < omission of low < omission of high reward. Contrast 
weights; 4 -1-6 -14). Signiﬁ  cant activation clusters are listed separately for each group and for the between group comparisons. The activations reported in healthy 
subjects and patients were signiﬁ  cant at p < 0.001 uncorrected for multiple comparisons on the voxel-level or as indicated (∼p < 0.005 FWE corrected; *p < 0.05 
FDR corrected 1), interactions in study 2 at p < 0.005 at the voxel-level. Coordinates are SPM/MNI.Frontiers in Behavioral Neuroscience  www.frontiersin.org  February 2010  | Volume 3  |  Article 62  |  6
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RESULTS
We investigated main effects of salience (controls, patients, on 
medication, off medication) and the interaction of salience by 
group (controls vs. patients, on vs. off medication) during the 
outcome phase.
STUDY 1 (INDEX STUDY)
Results from the salience contrast from the index study were taken 
directly from Walter et al. (2009).
STUDY 2 (REPLICATION STUDY)
Like in the index study, we found activation in the right VLPFC 
and adjacent anterior insula and anterior cingulate in controls but 
not in patients with schizophrenia. Replicating the result from the 
index study, the interaction contrast between healthy controls and 
patients diagnosed with schizophrenia showed differences in the 
VLPFC/anterior insula and furthermore the anterior cingulate 
cortex (Figure 2, Table 1).
The regression curve for the U-shaped contrast (Figure 2) in 
this study with the magnitude paradigm is ideally described with a 
parabolic line that can be characterized by the second order equa-
tion (2x² − 13x + 15 = y) with the coefﬁ  cient “a = 2” as a measure 
of the shape of the U. Parameter estimates were extracted from 
the peak voxel (33/30/−9) found for the interaction contrast that 
revealed the difference between healthy controls and patients with 
schizophrenia. Again, like in the index study, the values for the 
coefﬁ  cient “a” in the control subjects (a = 0.45) were signiﬁ  cantly 
higher than in the patients suffering from schizophrenia (a = −0.07; 
t = 3.39, p = 0.003).
Correlational analyses in study 2 and study 1
In the replication study 2, we found a signiﬁ  cant negative correla-
tion (r = −0.43, p = 0.03) of the Physical Anhedonia scores in all 
subjects, patients and controls and the coefﬁ  cient “a” characterizing 
the regression curves, that is, lower anhedonia scores predicted a 
pattern with more U-shaped curves more similar to the controls 
(Figure 2). The correlation was driven by the signiﬁ  cant correlation 
in the patients (r = -0.75, p = 0.02). In controls alone, the correla-
tion was not signiﬁ  cant (r = -0.23, p > 0.05 [0.24]). Likewise, in the 
index study 1, we found a signiﬁ  cant negative correlation (r = −0.34, 
p = 0.036) of the Social, but not Physical Anhedonia scores in all 
subjects, patients and controls and the coefﬁ  cient “a” characterizing 
the regression curves. However, this correlation was partly driven 
by the group differences in both, fMRI signal and anhedonia scores 
as can be seen in Figure 3.
Positive and Negative Syndrome Scale positive and negative 
scores did not correlate signiﬁ  cantly in the index or the replica-
tion study.
STUDY 3 (HEALTHY CONTROLS)
In the control study for the probability paradigm, we found activation 
in the right VLPFC (Figure 1, Table 2) for the salience contrast.
The regression curve for the U-shaped contrast in this study with 
the probability paradigm is ideally described with a parabolic line that 
can be characterized by the second order equation (1/3x² − 3x + 5 = y) 
with the coefﬁ  cient “a = 1/3” as a measure of the shape of the U. The 
value for the coefﬁ  cient “a” in this study was 0.21.
STUDY 4 (RLS-STUDY)
In this study using the probability paradigm, we found activa-
tion in the right VLPFC only when patients were off their regular 
medication with dopamine agonists. The coefﬁ  cient “a” that can 
be taken as a measure of the shape of the U of this contrast (see 
Section “Study 2”) had a value of a = 1.8 in the peak voxel of this 
activation (ideal value a = 1/3 for probability paradigm). The 
value of “a” in this voxel when patients were on their regular 
medication was 0.02. There was a trend for higher coefﬁ  cients “a” 
off medication (t = 1.7, p = 0.058) although no signiﬁ  cant inter-
action effect was found for the whole brain analysis in this region 
(Figure 3). On medication, the whole brain analysis revealed acti-
vation in the left VLPFC. However, inspection of the parameter 
estimates in this region revealed that this effect was mainly driven 
by highly positive values for the regressor o/75% and to a lower 
extent by the U-shape of the contrast which was quite far from 
ideal (a = 0.11).
STUDY 5 (OLANZAPINE STUDY)
We did not ﬁ  nd any signiﬁ  cant brain activation related to reward 
salience in the study comparing the effects of a single dose of olan-
zapine compared to placebo using the magnitude paradigm.
DISCUSSION
In this study, we investigated whether we could replicate our ﬁ  nd-
ing of aberrant salience coding in the right VLPFC observed in 
medicated patients with schizophrenia. Indeed, in an independent 
cohort of patients, the right VLPFC again showed a signiﬁ  cant 
decrease in salience coding in the patients. In both studies, aber-
rant salience coding proved to be related to negative symptoms 
as evidenced by negative correlations with anhedonia, which is in 
line with the revised dopamine hypothesis. Finally, we found only 
modest evidence that dopaminergic stimulation in patients with 
RLS might impact on the representation of reward salience in the 
right VLPFC.
ABERRANT SALIENCE CODING IN THE RIGHT VLPFC IN SCHIZOPHRENIA
It is noteworthy that we were able to demonstrate the involvement 
of the right VLPFC in salience coding in now four independent 
cohorts, independently of the reward parameter, that is, for reward 
magnitude as well as reward probability. As in our index study, 
the right VLPFC showed signiﬁ  cantly reduced activation in the 
salience contrast with correspondingly a signiﬁ  cantly smaller 
coefﬁ  cient “a” (Figure 1) in patients. Although two other cortical 
regions, namely the anterior cingulate cortex as well as the left 
superior frontal cortex showed a similar pattern, we focus our 
discussion on the VLPFC as it was the only region common to 
both, study 1 and 2.
The right VLPFC has been suggested to play a crucial role 
in the change of response strategies (Cools et al., 2002) as well 
as in response suppression (Arana et al., 2003) in the context 
of reward paradigms. Furthermore, the VLPC is involved in 
set shifts in problem-solving tasks (Goel and Vartanian, 2005). 
These functions are consistent with the hypothesized role of this 
brain region in salience processing according to the definition 
above: The experience of salient events, may they be positive 
or negative, is important to adapt future behavior. Therefore, Frontiers in Behavioral Neuroscience  www.frontiersin.org  February 2010  | Volume 3  |  Article 62  |  7
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VLPFC hypoactivation to salient events may help to explain 
deficits in planning, decision making and action selection fre-
quently observed in patients with psychosis. Accordingly, we 
would like to suggest that the dysfunctional activation of the 
right VLPFC related to salience processing found in our patients 
suffering from schizophrenia might reflect a deficit in trans-
forming the salience signals into actions. This suggestion is 
further strengthened by the findings that an important dimen-
sion of negative symptoms, anhedonia, was linked to aberrant 
salience coding in both studies. This correlation is consistent 
with the hypothesized role of a reduced dopaminergic tone 
in the prefrontal cortex by the revised dopamine hypothesis. 
Study 1 found a correlation with social anhedonia, study 2 a 
correlation with physical anhedonia. Thus it can be speculated 
that reduced dopaminergic tone contributes to different types 
of anhedonia.
Interestingly, concurrent with the aberrant salience hypoth-
esis of psychosis, altered activation of the right VLPFC cortex 
was reliably found in a meta-analyses of fMRI studies on non-
  psychotic relatives of patients with schizophrenia (Macdonald 
et al., 2008) where it was described as increased. A ﬁ  nding of 
increased regional activation in subjects at risk for schizophre-
nia in the face of usually decreased activation in patients with 
schizophrenia is found quite often and can be explained as a 
compensatory activation in subjects predisposed but not suffering 
from schizophrenia. Consistently, in patients actually suffering 
FIGURE 3 | SALIENCE in outcome (reward probability). Brain activation and 
beta weights in the right VLPFC/anterior insula as found for the contrast 
modelling salience scanned during the probability paradigm. Study 3 was 
performed in healthy controls (HC), study 4 in patients with RLS off and on their 
regular medication. The beta values were extracted from the maximum voxel of 
the demonstrated activation. The map was thresholded at p < 0.005 FWE 
corrected for healthy controls and at p < 0.001 at the voxel-level and at an extent 
threshold of p < 0.05 at the cluster-level in patients. The coefﬁ  cient “a” taken as 
a measure of the shape of a U-shaped regression curve indicates a more 
shallow curve the lower the levels in healthy controls. In RLS patients on regular 
medication, the coefﬁ  cient “a” taken as a measure of the shape of a U-shaped 
regression curve indicates a trend (p = 0.06) towards a more shallow curve. 
r/25%, r/50%, r/75%, 0%, 100%, o/25%, o/50%, o75%: receipt (r) or omission 
(o) of reward expected at 0%, 25%, 50%, 75% or 100%.Frontiers in Behavioral Neuroscience  www.frontiersin.org  February 2010  | Volume 3  |  Article 62  |  8
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from schizophrenia deﬁ  cits in tasks mediated by ventrolateral 
prefrontal brain regions like reversal learning paradigms (Waltz 
and Gold, 2007) or the Iowa Gambling Task (Ritter et al., 2004) 
have been repeatedly demonstrated.
EFFECTS OF DOPAMINERGIC MANIPULATIONS ON PREFRONTAL 
SALIENCE CODING
Although we could conﬁ  rm our main hypothesis and replicate the 
results from our index study and found correlations with psychpa-
thology according to our hypothesis, the results in the study using 
dopaminergic manipulation were not as clear as we had hoped. We 
could not demonstrate a decrease in salience coding by olanzapine. 
However, it should be noted that the olanzapine study (study 5) is 
also the only study in which salience coding in the VLPFC in healthy 
controls (here on placebo) could not be replicated. This might be 
due to the small number of subjects investigated (n = 8).
Concerning dopaminergic manipulation, the results are at least 
partially supporting an inﬂ  uence of dopamine on salience coding. 
Whereas RLS patients off medication showed salience coding in the 
right VLPFC, as well as in anterior cingulate cortex and DLPFC, 
these effects vanished when the patients were on medication. This 
could be explained by the fact that non-salient events are also coded 
as salient and that the right VLPFC therefore cannot properly dis-
tinguish between salient and non-salient stimuli.
However, it has to be noted that the group difference was not 
signiﬁ  cant and that the change in the “a” coefﬁ  cient only showed 
a statistical trend. Moreover, an interpretation is limited by the fact 
that the subjects included in this study were patients with RLS, a 
disease that is generally accepted to be linked to central dopamin-
ergic dysfunction, so that these effects cannot be interpreted in a 
straightforward manner. Also side effects of medication have to 
be taking into account. Reported side effects that could be related 
to altered salience processing are impaired impulse control and 
pathological gambling. Of our patients, none reported problems 
with impulse control or manifest pathological gambling, which 
was an exclusion criterion, although most patients had experienced 
nausea or dizziness (common side effects) when ﬁ  rst receiving the 
medication. However, nausea and dizziness commonly wear off 
over the course of several days or weeks of regular medication.
LIMITATIONS
Like in our index study, our results are limited by the fact that 
the patients with schizophrenia were treated with neuroleptics. 
For the ventral striatum it has been shown that atypical neurolep-
tics normalized the BOLD-response in comparison to untreated 
patients (Juckel et al., 2006a). Therefore, it could be the case that 
the results of aberrant salience coding are an effect of medication. 
Although we cannot exclude this possibility, it seems unlikely to us, 
as we did not only ﬁ  nd categorical differences, but also a relation to 
psychopathology. Nevertheless, salience coding should be tested in 
non-medicated patients, an analysis that can easily be performed 
post hoc in studies already executed, a procedure we would like to 
encourage the respective groups to perform.
Furthermore, study 5 is limited not only by the small number 
of subjects but also by the fact that olanzapine is not a purely anti-
dopaminergic drug but acts on a range of different neurotransmit-
ters. As already mentioned, study 4 is limited by the fact that subjects 
are diagnosed having a disease impacting on central dopamine 
metabolism. Ideally, one would investigate a large group of healthy 
controls with one type of dopamine agonist, one type of a pure 
dopamine antagonist and a placebo.
CONCLUSION
In four of ﬁ  ve studies we could replicate a signiﬁ  cant activation of 
the right VLPFC for the processing of salience. Our main hypoth-
esis concerning schizophrenia was conﬁ  rmed: We could replicate 
the result of aberrant salience coding in the right VLPFC in an 
independent cohort of medicated patients with schizophrenia. 
Furthermore, the negative correlations with anhedonia scores pro-
vide evidence that aberrant salience coding is clinically relevant. An 
explanation of our replicated ﬁ  nding could be a low level of cortical 
dopamine, as postulated by the revised dopamine hypothesis. We 
suggest that future studies investigating reward in schizophrenia 
should, in addition to analysing prediction and prediction errors, 
pay more attention to salience coding.
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